Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Anju Ghangurde
With a broader ecosystem of prescription influencers emerging rapidly in India, pharma needs to engage with these groups extensively, a conference in Mumbai hears.
Novartis’s breast cancer therapy Piqray is endorsed by an expert panel for marketing in India and the Swiss company has emphasized its commitment to value-based pricing for the product.
Zentiva has struck a deal to acquire a manufacturing site in Ankleshwar, India, from its former parent company Sanofi.
Sanofi sells Indian facility to Zentiva, a key customer for products made at the site, and hopes to make up for the earnings gap through a renewed push for its “core activities and brands.”
Natco has sprung a challenge to Novartis’ vildagliptin patent in India, months before its expiry. The Indian firm will hold back further release of its product on the market amid legal action and it remains to be seen if Novartis will pursue damages.
Mylan’s proposal to progress studies for its aflibercept biosimilar has been endorsed by an expert panel in India, which expects availability of such biosimilars to expand access to anti-VEGF therapies.